XinchaoTuo® (Sacubitril Aalisartan Calcium Tablets), China's First Indigenous ARNI Antihypertensive Drug, Launches Exclusively Online via JD Health

Recently, the new hypertension drug XinchaoTuo^®(Sacubitril Valsartan Calcium Tablets) Made Their Online Debut on JD Health. Independently developed by Salubris Pharmaceuticals, this drug is China’s first original ARNI (angiotensin receptor-neprilysin inhibitor) antihypertensive medication, offering superior and safer blood pressure control. Leveraging its position as the primary online gateway for health consumption, along with its omni-channel supply chain and comprehensive healthcare service capabilities, JD Health aims to provide new treatment options for a broader population of hypertensive patients.

Hypertension is one of the most prevalent chronic diseases in China, characterized by a large patient population but concerning control rates. Data from the Chinese Guidelines for the Prevention and Treatment of Hypertension indicate that the control rate of hypertension among adults in China is only 16.8%. This situation stems not only from patients’ insufficient awareness of the disease but also from suboptimal selection of treatment modalities and poor adherence to therapy.

In recent years, in-depth research into hypertension and its complications, along with the emergence of new therapeutic strategies and novel drugs, has brought new hope to patients. Compared with traditional antihypertensive agents, angiotensin receptor-neprilysin inhibitors (ARNIs) feature a dual blood pressure-lowering mechanism: on one hand, they inhibit neprilysin-mediated degradation of natriuretic peptides, thereby exerting diuretic, natriuretic, and vasodilatory effects; on the other hand, they block angiotensin receptors to prevent compensatory activation of the renin-angiotensin system (RAS), achieving synergistic blood pressure reduction. Studies have confirmed that ARNIs can significantly reduce both office blood pressure and 24-hour ambulatory blood pressure in patients with resistant hypertension, thereby improving the rate of blood pressure control. The latest edition of the Chinese Guidelines for the Prevention and Treatment of Hypertension has recommended ARNIs as one of the commonly used medications for both initial and maintenance therapy of hypertension.

Xinchaotuo^®As the first ARNI drug independently developed in China, it has broken through the technical barriers of co-crystal drugs, becoming the second ARNI co-crystal drug globally. Its innovative design achieves simultaneous peak concentrations of the active metabolite of sacubitril and allisartan, prolongs the half-life of allisartan, and demonstrates a more favorable trend in blood pressure control. Notably, ARNI drugs not only provide potent antihypertensive effects but also offer cardiorenal protection, making them particularly suitable for patients with hypertension complicated by heart failure or chronic kidney disease.

A representative from Salubris Pharmaceuticals stated that hypertension is a key therapeutic area for the company. In addition to Xinchuotuo, Salubris has established a comprehensive portfolio of original allisartan-based antihypertensive medications, ranging from monotherapies to combination therapies, to address patients with varying levels of hypertension. This portfolio includes the ARB monotherapy Xinlitan (Allisartan Isoproxil Tablets) and the single-pill combination formulation Fulitan.^®(Allisartan Isoproxil and Amlodipine Tablets), Fulian^®(Allisartan Isoproxil and Indapamide Sustained-Release Tablets).

A JD Health representative stated, “JD Health has always been committed to providing consumers with high-quality pharmaceutical and healthcare products and services. This collaboration with Salubris will fully leverage our capabilities and advantages to support Xinchao Tuo”^®"This domestically developed innovative drug rapidly reaches a broader patient population, jointly promoting the improvement of hypertension prevention and control in China."

In recent years, the value proposition of JD Health’s “Primary Launch Platform for New and Specialty Drugs” has continued to expand. A wide range of cutting-edge innovative medicines have reached a broad patient population through JD Health, providing them with more precise, efficient, and improved treatment experiences. Looking ahead, JD Health will collaborate with global pharmaceutical partners to further enhance the accessibility of new and specialty drugs, helping more patients receive scientific and precise disease treatments.